First Page | Document Content | |
---|---|---|
![]() Date: 2014-04-14 15:46:12Fingolimod Immunosuppressants Multiple sclerosis Pharmacometrics Dose-response relationship Biomarker Sphingosine-1-phosphate Medicine Pharmacology Diols | Source URL: www.nature.comDownload Document from Source WebsiteFile Size: 493,60 KBShare Document on Facebook |
![]() | PDF DocumentDocID: 194Bg - View Document |
![]() | Microsoft PowerPoint - SphK1_ColoCa_ClinicalTransGastro[removed]T_FiguresRev_09Dec2013.pptxDocID: ZYbk - View Document |
![]() | A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagyDocID: ZRhe - View Document |
![]() | OPEN Citation: Cell Death and Disease[removed], e927; doi:[removed]cddis[removed] & 2013 Macmillan Publishers Limited All rights reserved[removed]www.nature.com/cddisDocID: ZGLs - View Document |
![]() | Treatments for MS: Gilenya ® (fingolimod) There are currently several disease-modifying therapies approved for people with MS inDocID: Xydz - View Document |